Premium
A COMPARATIVE BIOAVAILABILITY STUDY OF MOLIPAXIN CAPSULES AND A TRAZODONE LIQUID FORMULATION IN NORMAL VOLUNTEERS
Author(s) -
Harcus A. W.,
Ward A. E.,
Ankier S. I.,
Kimber G. R.
Publication year - 1983
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.1983.tb01041.x
Subject(s) - bioavailability , trazodone , pharmacology , medicine , antidepressant , hippocampus
SUMMARY The pharmacokinetic parameters of Molipaxin capsules and a trazodone liquid formulation have been compared in healthy volunteers. The mean area under the plasma concentration/time curve was 10.07 μg h ml ‐1 and 10.44 μg h ml ‐1 , for Molipaxin capsules and trazodone liquid, respectively. The difference was not statistically significant. There was considerable individual variation between the observed maximum plasma concentration of Molipaxin capsules and trazodone liquid but the mean values of 1.61 μg/ml and 1.66 μg/ml, respectively, were very similar. The time to observed maximum plasma concentrations varied from 15 min to 4 h, but there was no statistical difference between the two formulations. The terminal phase half‐life was 7.16 h for Molipaxin capsules and 6.73 h for trazodone liquid. The difference was not statistically significant. Molipaxin capsules and trazodone liquid have similar kinetic profiles and they are considered to have comparable bioavailability. Tolerance to the two formulations was similar.